Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Breast 4Thoracic 3Gynecologic 3Plasma cell 2Head & Neck 2Genitourinary 2Endocrine 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1

Conditions

Urogenital Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

lutetium Lu 177 dotatate 5Specimen Handling 4Magnetic Resonance Spectroscopy 4cabozantinib 3olaparib 2fludarabine 2X-Rays 2Phantoms, Imaging 2Cyclophosphamide 2tivozanib 1repotrectinib 1pembrolizumab 1pazopanib 1fludarabine phosphate 1entrectinib 1belinostat 1atezolizumab 1aldesleukin 1Yttrium-90 1Temozolomide 1Sunitinib 1Salts 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1Introns 1Interferon alpha-2 1Immunoglobulin G 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
aldesleukin × NET × 30 days × Clear all
NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡